The mysteries of the Falsified Medicines Directive - where is the logic on safety features?
This article was originally published in SRA
Executive Summary
The European Commission says that pharmaceutical companies whose products are not covered by the Falsified Medicines Directive will be prohibited from applying safety features on a voluntary basis. This, Peter Bogaert and Cynthia Burton argue, is contrary to the aims of the directive – to protect public health.